Hepion Pharmaceuticals, Inc.
OTC: HEPA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gary S. Stetz
- Employees
- 22
- Headquarters
- Edison, United States
- IPO year
- 2014
- Market cap
- $617.7K
- Website
- https://www.hepionpharma.com
Loading HEPA…
Loading profile data…Frequently asked questions about HEPA
What does Hepion Pharmaceuticals, Inc. (HEPA) do?
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways imp...
Where does HEPA trade?
Hepion Pharmaceuticals, Inc. (HEPA) trades on the Other OTC.
What sector is HEPA in?
Hepion Pharmaceuticals, Inc. (HEPA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Hepion Pharmaceuticals, Inc.?
Gary S. Stetz is the chief executive officer of Hepion Pharmaceuticals, Inc. (HEPA).
Where is Hepion Pharmaceuticals, Inc. headquartered?
Hepion Pharmaceuticals, Inc. is headquartered in United States.
Does HEPA pay a dividend?
Hepion Pharmaceuticals, Inc. (HEPA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did HEPA go public?
Hepion Pharmaceuticals, Inc. (HEPA) completed its initial public offering in 2014.